TNF inhibitors | Non-TNF inhibitors | |||||||
---|---|---|---|---|---|---|---|---|
Patients (n) | Adalimumab | Certolizumab pegol | Etanercept | Golimumab | Infliximab | Abatacept | Rituximab | Tocilizumab |
Denmark | 1212 | 1444 | 2816 | 434 | 1528 | 1109 | 984 | 1703 |
Finland | 666 | 428 | 1018 | 517 | 241 | 544 | 910 | 442 |
Norway | 102 | 460 | 468 | 150 | 208 | 92 | 223 | 173 |
Sweden | 2984 | 2012 | 6529 | 1861 | 2714 | 2701 | 3488 | 2477 |
TOTAL | 4964 | 4344 | 10 831 | 2962 | 4691 | 4446 | 5605 | 4795 |
Any history of cancer | Adalimumab | Certolizumab pegol | Etanercept | Golimumab | Infliximab | Abatacept | Rituximab | Tocilizumab |
Denmark N (%) patients with history of cancer N patients with in situ/invasive cancer | 12 (1%) 5/7 | 26 (1.8%) 17/9 | 53 (1.9%) 22/31 | 5 (1.2%) <5/<5 | 27 (1.8%) 11/16 | 16 (1.4%) 6/10 | 169 (17.2%) 17/152 | 36 (2.1%) 18/18 |
Finland N (%) of patients with any history of cancer N. patients with in situ/invasive cancer | 16 (2.4%) 1/15 | 16 (3.7%) 2/14 | 35 (3.4%) 2/33 | 20 (3.8%) 2/18 | 8 (3.3%) 3/5 | 44 (8%) 5/39 | 118 (13%) 3/115 | 31 (7%) 2/28 |
Norway N (%) of patients with any history of cancer N. patients with in situ/invasive cancer | 2 (2.0%) N/A | 7 (1.5%) N/A | 6 (1.3%) N/A | 3 (2.0%) N/A | 5 (2.4%) N/A | 1 (1.0%) N/A | 26 (11.7%) N/A | 6 (3.5%) N/A |
Sweden N (%) patients with any history of cancer N. patients with in situ/invasive cancer | 152 (5.1%) 61/91 | 108 (5.3%) 31/77 | 397 (6.1%) 142/255 | 83 (4.5%) 38/45 | 139 (5.1%) 59/80 | 186 (6.9%) 63/123 | 493 (14%) 98/395 | 145 (5.9%) 45/100 |
ALL N (%) patients with any history of cancer | 182 (3.7%) | 157 (3.6%) | 491 (4.5%) | 111 (3.7%) | 179 (3.8%) | 247 (5.6%) | 806 (14.4%) | 218 (4.5%) |
Time (years) since cancer*, median (IQR) | Adalimumab | Certolizumab pegol | Etanercept | Golimumab | Infliximab | Abatacept | Rituximab | Tocilizumab |
Denmark | 4 (2–5) | 7 (2–7) | 3 (2–6) | 4 (4–7) | 5 (2–7) | 4 (2–7) | 3 (1–6) | 6 (3–8) |
Finland | 5 (4–6) | 4 (2–5) | 4 (2–6) | 3 (1–6) | 3 (2–6) | 3 (4–6) | 3 (2–6) | 3 (1–5) |
Norway | <5 patients | 7 (5–8) | 6 (3–9) | <5 patients | 5 (2–9) | <5 patients | 2 (2–5) | 6 (2–8) |
Sweden | 4 (2–6) | 4 (2–7) | 4 (2–7) | 4 (2–7) | 4 (2–7) | 4 (2–6) | 3 (1–6) | 4 (2–7) |
Median (IQR) age at bDMARD start, years | Adalimumab | Certolizumab pegol | Etanercept | Golimumab | Infliximab | Abatacept | Rituximab | Tocilizumab |
Denmark
| 56 (46–65) 63 (55–70) | 57 (48–66) 52 (41–67) | 59 (50–68) 60 (47–73) | 56 (45–66) 60 (60–70) | 60 (49–69) 60 (47–73) | 59 (50–68) 63 (47–71) | 61 (52–70) 66 (58–73) | 59 (50–69) 61 (43–71) |
Finland
| 51 (43–61) 62 (56–70) | 53 (44–62) 63 (55–69) | 52 (41–63) 66 (59–70) | 52 (43–62) 67 (60–69) | 48 (37–59) 59 (54–62) | 56 (48–65) 65 (61–72) | 63 (56–71) 68 (61–75) | 54 (51–61) 66 (57–72) |
Norway
| 52 (50–54) <5 patients | 54 (53–55) 64 (60–75) | 53 (52–53) 63 (57–75) | 52 (50–53) <5 patients | 55 (53–56) <5 patients | 54 (53–56) <5 patients | 58 (56–59) 63 (58–69) | 54 (53–55) 67 (52–68) |
Sweden
| 58 (46–67) 67 (57–72) | 58 (47–67) 67 (52–74) | 58 (46–67) 67 (56–73) | 58 (46–66) 65 (50–71) | 59 (48–67) 65 (55–73) | 61 (51–69) 69 (61–75) | 64 (54–72) 68 (61–74) | 59 (48–67) 65 (58–73) |
Female, % | Adalimumab | Certolizumab pegol | Etanercept | Golimumab | Infliximab | Abatacept | Rituximab | Tocilizumab |
Denmark
| 78% 83% | 75% 85% | 77% 85% | 74% <5 patients | 75% 74% | 79% 75% | 78% 77% | 77% 78% |
Finland
| 73% 69% | 75% 88% | 78% 86% | 76% 80% | 70% 100% | 84% 91% | 74% 76% | 78% 71% |
Norway
| 85% <5 patients | 75% 71% | 76% 100% | 77% <5 patients | 73% <5 patients | 84% <5 patients | 77% 64% | 84% 71% |
Sweden
| 76% 79% | 76% 77% | 77% 78% | 78% 78% | 74% 72% | 81% 82% | 76% 71% | 80% 77% |
Prior bDMARDs (n; median, IQR) | Adalimumab | Certolizumab pegol | Etanercept | Golimumab | Infliximab | Abatacept | Rituximab | Tocilizumab |
Denmark
| 1 (0–2) 0 (0–0) | 1 (0–2) 0 (0–0) | 1 (0–2) 0 (0–0) | 1 (0–2) 0 (0–1) | 1 (0–2) 0 (0–1) | 1 (0–2) 0 (0–0) | 0 (0–2) 0 (0–0) | 1 (0–2) 0 (0–0) |
Finland
| 0 (0–1) 0 (0–1) | 1 (0–2) 2 (1–4) | 0 (0–1) 0 (0–1) | 0 (0–2) 1 (0–3) | 0 (0–1) 0 (0–2) | 1 (0–2) 1 (0–2) | 0 (0–2) 0 (0–1) | 2 (1–3) 1 (0–3) |
Norway
| 1 (0–1) <5 patients | 0 (0–1) 0 (0–0) | 0 (0–1) 1 (0–2) | 1 (0–2) <5 patients | 0 (0–1) <5 patients | 3 (2–4) <5 patients | 2 (1–2) 0 (0–1) | 2 (1–3) 3 (1–3) |
Sweden
| 1 (0–1) 1 (0–2) | 0 (0–2) 0 (0–2) | 0 (0–1) 0 (0–1) | 1 (0–1) 1 (0–2) | 0 (0–1) 0 (0–1) | 2 (1–3) 1 (1–3) | 1 (0–2) 1 (0–2) | 2 (1–3) 2 (1–3) |
*Time from cancer diagnosis was defined as the time from first diagnosis of cancer until the start of the bDMARD.
TNF, tumor necrosis factor; IQR, interquartile range; bDMARD, biologic disease-modifying anti-rheumatic drug; N/A, non-available.